Business
Positive phase III data for GSK's RSV OA vaccine
Positive phase III data for GSK's RSV OA vaccine.
About this update from Gsk Plc
[{"type":"text","content":"\n \n \n Issued: 10 June 2022, London UK - LSE Announcement\n \n \n \n \n \n \n \n \n GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults\n \n \n \n \n \n \n ·\n First RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adults aged 60 years and above\n \n \n ·\n The magnitude of effect observed was consistent across RSV A and B strains, key secondary endpoints and in those aged 70 years and above\n \n \n ·\n Engagement with regulators to start immediately with anticipated regulatory submissions in H2 2022\n \n \n \n \n \n \n GSK plc (LSE/NYSE: GSK) today announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial. The interim analysis was reviewed by an Independent Data Monitoring Committee, and the primary endpoint was exceeded with no unexpected safety concerns observed. AReSVi 006 is a phase III trial investigating GSK's respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above.\n \n \n \n \n \n \n Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK\n \n , said: \"These data suggest our RSV vaccine candidate offers exceptional protection for older adults from the serious consequences of RSV infection. RSV remains one of the few major infectious diseases without a vaccine, and these data have the potential to meaningfully impact the treatment of RSV and may reduce the 360,000 hospitalisations and more than 24,000 deaths worldwide each year. Given the importance of these data, we plan to engage with regulators immediately and anticipate regulatory submissions in the second half of 2022.\"\n \n \n \n \n \n Results from this phase III trial will be presented in a peer-reviewed publication and at an upcoming scientific meeting. The AReSVi 006 trial will continue to evaluate both an annual revaccination schedule and longer-term protection over multiple seasons following one dose of the RSV older adult (OA) vaccine candidate.\n \n \n \n \n \n GSK's RSV OA vaccine candidate contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK's proprietary AS01 adjuvant. AS01 is used with several of GSK's established adjuvante...